Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarker Helps Predict Stomach Cancer Survival

By LabMedica International staff writers
Posted on 16 Sep 2015
A biomarker has been identified in patients with stomach cancer that starves tumors of their blood supply and reduces the ability of cancer cells to spread to other parts of the body. More...


In the USA, stomach cancer, also known as gastric cancer, most commonly affects older people, as around 60% of those diagnosed each year are over 65. Stomach cancer is most common in less developed countries, and it is a primary cause of cancer-related deaths worldwide.

Scientists at the Southern Medical University (Guangzhou, China) used a form of genetic analysis called quantitative real-time polymerase chain reaction (qRT-PCR) to detect micro ribonucleic acid 506 (miR-506) in human gastric samples taken from 84 people who had undergone cancer surgery. The team analyzed the miR-506 levels in each of these samples, and patients were allocated to different groups based on whether they were above or below the mean miR-506 level.

They found that miR-506 expression was a useful marker for stratifying patients from early to advanced clinical stages and for overall survival prediction. Overexpression of miR-506 inhibited the epithelial-to-mesenchymal transition of gastric cancer cells; however, depletion of miR-506 promoted it. In addition, miR-506 suppressed gastric cancer angiogenesis and was associated with decreased matrix metalloproteinase-9 expression. They also found that V-Ets Avian Erythroblastosis virus E26 Oncogene Homolog 1 (ETS1) was a miR-506 target, and it was expressed in 71.10% of gastric cancer tissue samples. At 60 months, cumulative survival was approximately 30% in the low-miR-506 expression group, compared with 80% in the high-expression group.

The team then looked at signs of miR-506 in seven stomach cancer cell lines. Here, it was found that stomach cancer cells had lower levels of miR-506 than normal stomach tissue. Analysis of cells grown in vitro then showed that miR-506 levels were lowest in the cell lines that had the highest invasive activity, and the highest levels were seen in cell lines with the lowest invasive activity.

Xin Song, MD, PhD, the lead investigator, said, “Our findings indicate that miR-506 is necessary and sufficient for angiogenesis suppression during gastric cancer progression. Cancer is a complex disease and controlling cancer development and progression requires system level and integrative approaches. Our study suggests that miR-506 acts as a tumor suppressor in gastric cancer." The study was published on September 8, 2015, in the American Journal of Pathology.

Related Links:

Southern Medical University 



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.